Purpose: To characterize the utility of monitoring transcranial electrical motor evoked potentials (TCeMEPs) and somatosensory evoked potentials (SSEPs) for neural thermoprotection during musculoskeletal tumor ablations. Materials and Methods: Retrospective review of 29 patients (16 male; median age, 46 y; range, 7–77 y) who underwent musculoskeletal tumor radiofrequency ablation (n ¼ 8) or cryoablation (n ¼ 22) with intraprocedural TCeMEP and SSEP monitoring was performed. The most common tumor histologies were osteoid osteoma (n ¼ 6), venous malformation (n ¼ 5), sarcoma (n ¼ 5), renal cell carcinoma (n ¼ 4), and non–small-cell lung cancer (n ¼ 3). The most common tumor sites were spine (n ¼ 22) and lower extremities (n ¼ 4). Abnormal TCeMEP change was defined by 100-V increase above baseline threshold activation for a given myotome; abnormal SSEP change was defined by 60% reduction in baseline amplitude and/or 10% increase in latency. Results: Abnormal changes in TCeMEP (n ¼ 9; 30%) and/or SSEP (n ¼ 5; 17%) occurred in 12 procedures (40%) and did not recover in 5 patients. Patients with unchanged TCeMEP/SSEP activities throughout the procedure (n ¼ 18) did not have motor or sensory symptoms after the procedure; 3 (60%) with unrecovered activity changes and 2 (29%) with transient activity changes had new motor (n ¼ 1) or sensory (n ¼ 4) symptoms. Relative risk for neurologic sequelae for patients with unrecovered TCeMEP/SSEP changes vs those with transient or no changes was 7.50 (95% confidence interval, 1.66–33.9; P ¼ .009). Conclusions: Abnormal activity changes of TCeMEP or SSEP during percutaneous ablative procedures correlate with postprocedural neurologic sequelae.
|VI – 2016||Procedures|
|Abdominal Angiography and Intervention, GU and GI Nonvascular Procedures||1.00|
|VI – 2017||Procedures|